Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV.
CD8-Positive T-Lymphocytes
/ immunology
Clinical Trials, Phase I as Topic
Cytomegalovirus
/ immunology
Cytomegalovirus Infections
/ immunology
Cytomegalovirus Vaccines
/ administration & dosage
Humans
Kidney Failure, Chronic
/ immunology
Kidney Transplantation
Receptors, Antigen, T-Cell
/ genetics
Sequence Analysis, RNA
Single Molecule Imaging
Viral Matrix Proteins
/ administration & dosage
CMV
TCR motif
end-stage renal disease
peptide vaccination
single-cell sequencing
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Jan 2022
18 Jan 2022
Historique:
received:
01
12
2021
revised:
12
01
2022
accepted:
14
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
9
3
2022
Statut:
epublish
Résumé
After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal disease listed for kidney transplantation were subjected to CMV phosphoprotein 65 (CMVpp65) peptide vaccination and further investigated for T-cell responses. To this end, CMV-specific CD8
Identifiants
pubmed: 35162953
pii: ijms23031029
doi: 10.3390/ijms23031029
pmc: PMC8835207
pii:
doi:
Substances chimiques
Cytomegalovirus Vaccines
0
Receptors, Antigen, T-Cell
0
Viral Matrix Proteins
0
cytomegalovirus matrix protein 65kDa
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Baden-Württemberg Stiftung (Michael Platten)
ID : BWST_ISF2018-046
Organisme : Else Kröner-Fresenius Foundation (EKMS) and Deutsche Forschungsgemeinschaft, (Lukas Bunse)
ID : SFB 1389-B03
Organisme : The CMVPepVac Study Scientific Committee designed the study, reviewed the study data and statistical analysis, and wrote the report. All authors had full access to the study data, decided to submit the report for publication, assume responsibility for the
ID : SFB 1389-B03
Références
Bioinformatics. 2019 Sep 1;35(17):2974-2981
pubmed: 30657870
Kidney Int. 2002 Jul;62(1):319-28
pubmed: 12081594
Kidney Int. 2004 Jul;66(1):329-37
pubmed: 15200441
Am J Kidney Dis. 2011 Jul;58(1):118-26
pubmed: 21684438
J Immunol. 2019 Feb 1;202(3):979-990
pubmed: 30587531
Nucleic Acids Res. 2018 Jan 4;46(D1):D419-D427
pubmed: 28977646
Transplant Rev (Orlando). 2016 Jul;30(3):119-43
pubmed: 27132815
J Infect Dis. 2008 Jun 15;197(12):1634-42
pubmed: 18444883
Transpl Int. 2018 Apr;31(4):436-450
pubmed: 29284181
Cell Rep. 2017 Apr 18;19(3):569-583
pubmed: 28423320
Nat Immunol. 2020 Oct;21(10):1205-1218
pubmed: 32839608
Am J Transplant. 2010 Sep;10(9):2026-32
pubmed: 20883536
Vaccine. 2016 Jan 12;34(3):313-9
pubmed: 26657184
PLoS Biol. 2019 Jun 13;17(6):e3000314
pubmed: 31194732
Transpl Immunol. 2004 Jun-Jul;13(1):55-61
pubmed: 15203129
Lancet Haematol. 2016 Feb;3(2):e87-98
pubmed: 26853648
Nature. 2021 Apr;592(7854):463-468
pubmed: 33762734
Vaccine. 2019 Nov 28;37(50):7437-7442
pubmed: 29622379
Blood. 1991 Sep 1;78(5):1373-80
pubmed: 1652311
Vaccines (Basel). 2014 Jul 02;2(3):515-36
pubmed: 26344743
Lancet Infect Dis. 2012 Apr;12(4):290-9
pubmed: 22237175
Nat Genet. 2017 May;49(5):659-665
pubmed: 28369038
Kidney Int. 2012 Jul;82(2):212-9
pubmed: 22495292
Immunity. 2016 Dec 20;45(6):1270-1284
pubmed: 27939671
Transpl Int. 2014 Jul;27(7):643-56
pubmed: 24629072
Lancet. 2005 Jun 18-24;365(9477):2105-15
pubmed: 15964447
N Engl J Med. 2009 Mar 19;360(12):1191-9
pubmed: 19297572
Vaccines (Basel). 2021 Feb 06;9(2):
pubmed: 33562163
Curr Opin Virol. 2018 Feb;28:161-166
pubmed: 29459261
J Immunol Methods. 2009 Apr 15;343(2):140-7
pubmed: 19248785